Erkut Borazanci

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bruno Bockorny, Valerya Semenisty, Teresa Macarulla et al. · Nature Medicine · 2020 · 501 citations

Cxcr4 Antagonist, Oncology, Pancreatic Cancer +8

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

Yu Shi, Weina Gao, Nikki K. Lytle et al. · Nature · 2019 · 413 citations

Tumor Biology, Drug Targeting, Pancreatic Cancer +8

Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions

Wei Lin, Pawan Noel, Erkut Borazanci et al. · Genome Medicine · 2020 · 320 citations · Full text

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer

Thomas B. Karasic, Mark H. O’Hara, Arturo Loaiza‐Bonilla et al. · JAMA Oncology · 2019 · 277 citations · Full text

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau et al. · EClinicalMedicine · 2021 · 250 citations · Full text